Literature DB >> 21866351

Mutagenicity of diagnostic and therapeutical doses of radiopharmaceutical iodine-131 in Wistar rats.

Elisângela Düsman1, Alessandra Paim Berti, Rosinete Gonçalves Mariucci, Nilson Benedito Lopes, Veronica Elisa Pimenta Vicentini.   

Abstract

Iodine-131 ((131)I) is a radioisotope used for the diagnosis and treatment of thyroidal disorders such as hyperthyroidism and cancer. During its decay, (131)I emits beta particles and gamma rays; its physical half-life is 8 days, and it is accumulated preferentially in the thyroid tissue. This study aimed to evaluate the cytotoxicity and mutagenicity of diagnostic and therapeutic doses of (131)I using bone marrow cells of rats treated in vivo in a test system with a single dose by gavage. Concentrations of 5, 25, 50 and 250 μCi in 1 ml of water were used, and after 24 h, the animals were killed. Also, a concentration of 25 μCi/ml of water was used, and the animals were killed after 5 days. The results showed that no concentration of (131)I was cytotoxic and that all concentrations were mutagenic. As a result, there was no statistically significant difference detected by the χ(2) test in the induction of chromosomal aberrations between the different doses. Thus, the present study demonstrated a significant increase in chromosomal aberration in bone marrow cells exposed to (131)I regardless of the dose or the treatment time.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21866351     DOI: 10.1007/s00411-011-0380-y

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  22 in total

1.  Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy.

Authors:  O Monteiro Gil; N G Oliveira; A S Rodrigues; A Laires; T C Ferreira; E Limbert; A Léonard; G Gerber; J Rueff
Journal:  Mutagenesis       Date:  2000-01       Impact factor: 3.000

2.  Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131.

Authors:  Michela Ballardin; Federica Gemignani; Lisa Bodei; Giuliano Mariani; Marco Ferdeghini; Anna Maria Rossi; Lucia Migliore; Roberto Barale
Journal:  Mutat Res       Date:  2002-02-15       Impact factor: 2.433

3.  Micronuclei induction by 131I exposure: study in hyperthyroidism patients.

Authors:  S Gutiérrez; E Carbonell; P Galofré; A Creus; R Marcos
Journal:  Mutat Res       Date:  1997-01-03       Impact factor: 2.433

4.  Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance.

Authors:  C Reiners; M Lassmann
Journal:  Eur J Nucl Med       Date:  1999-07

5.  Application of the single cell gel electrophoresis (SCGE) assay to the detection of DNA damage induced by 131I treatment in hyperthyroidism patients.

Authors:  S Gutiérrez; E Carbonell; P Galofré; A Creus; R Marcos
Journal:  Mutagenesis       Date:  1998-01       Impact factor: 3.000

6.  No evidence of increased chromosomal aberrations and micronuclei in lymphocytes from nonfamilial thyroid cancer patients prior to radiotherapy.

Authors:  O M Gil; N G Oliveira; A S Rodrigues; A Laires; T C Ferreira; E Limbert; J Rueff
Journal:  Cancer Genet Cytogenet       Date:  2000-11

7.  Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.

Authors:  Lebana J Joseph; Uma S Bhartiya; Yogita S Raut; Purushottam Kand; Rohini W Hawaldar; Narendra Nair
Journal:  Mutat Res       Date:  2009-02-11       Impact factor: 2.433

8.  Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism.

Authors:  S F Barrington; P Anderson; A G Kettle; R Gadd; W H Thomson; S Batchelor; P J Mountford; L K Harding; M J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

Review 9.  [Radioiodine therapy for differentiated thyroid carcinoma: methods used to increase the radiation absorbed dose].

Authors:  Marcelo Tatit Sapienza; Irene Shimura Endo; Guilherme C Campos Neto; Marcia G M Tavares; Marília M S Marone
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-03-16

10.  No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis.

Authors:  Giovanni Federico; Giuseppe Boni; Barbara Fabiani; Lisa Fiore; Patrizia Lazzeri; Francesco Massart; Claudio Traino; Carmela Verola; Giuseppe Saggese; Giuliano Mariani; Roberto Scarpato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-22       Impact factor: 9.236

View more
  1 in total

1.  Radioprotective effect of the Barbados Cherry (Malpighia glabra L.) against radiopharmaceutical iodine-131 in Wistar rats in vivo.

Authors:  Elisângela Düsman; Alessandra Paim Berti; Rosinete Gonçalves Mariucci; Nilson Benedito Lopes; Lilian Tatiani Düsman Tonin; Veronica Elisa Pimenta Vicentini
Journal:  BMC Complement Altern Med       Date:  2014-01-31       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.